Literature DB >> 7973114

Posttraumatic endophthalmitis. Causative organisms, treatment, and prevention.

D V Alfaro1, D Roth, P E Liggett.   

Abstract

BACKGROUND: Posttraumatic endophthalmitis is a rare complication of penetrating eye injuries that results in blindness in potentially salvageable eyes.
METHODS: 36 cases of posttraumatic endophthalmitis were evaluated retrospectively to determine which factors were associated with visual loss. All cases were treated with intravenous and intraocular antibiotics. Pars plana vitrectomy was performed in 15 (41.7%) cases as an adjunct to treatment.
RESULTS: Patients ranged in age from 18 months to 83 years, and included 30 men (83%) and 6 women (17%). Intraocular foreign bodies were present in 6 patients (16.7%), 9 (25%) had corneal lacerations, 13 (36.1%) had corneoscleral or scleral lacerations, and 8 (22.2%) had ocular trauma of unknown type. Of the 36 eyes, 21 (58.3%) had positive culture results, and 10 of these (27.8%) had multiple organisms. The most common isolates were Staphylococcus species (26.5%), Streptococcus species (20.6%), and Bacillus species (14.7%). In 4 cases the diagnosis was made 6 or more years after injury. Final visual acuity was 20/200 in 8 eyes (22.2%) and 20/300 in 1 eye. In 17 cases (47.2%), the eye was salvaged but visual acuity was 5/200 or worse, and 10 eyes (27.8%) were lost to enucleation or phthisis bulbi.
CONCLUSION: Prompt diagnosis and early treatment with intraocular and systemic antibiotics are important in the successful management of posttraumatic endophthalmitis. The use of pars plana vitrectomy was associated with a good visual outcome when used in select cases.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7973114

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  15 in total

Review 1.  The microbiology of endophthalmitis: global trends and a local perspective.

Authors:  Y Keynan; Y Finkelman; P Lagacé-Wiens
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-06-05       Impact factor: 3.267

Review 2.  Endophthalmitis following open-globe injuries.

Authors:  Y Ahmed; A M Schimel; A Pathengay; M H Colyer; H W Flynn
Journal:  Eye (Lond)       Date:  2011-12-02       Impact factor: 3.775

3.  Diagnostic pars plana vitrectomy report of a 21-year retrospective study.

Authors:  G N Palexas; W R Green; M F Goldberg; Y Ding
Journal:  Trans Am Ophthalmol Soc       Date:  1995

4.  Assessment of a standard treatment protocol on visual outcome following presumed bacterial endophthalmitis.

Authors:  N Okhravi; H M Towler; P Hykin; M Matheson; S Lightman
Journal:  Br J Ophthalmol       Date:  1997-09       Impact factor: 4.638

5.  Experimental Bacillus cereus post-traumatic endophthalmitis and treatment with ciprofloxacin.

Authors:  D V Alfaro; J Davis; S Kim; F Bia; J F Bogard; J W Briggs; P E Liggett
Journal:  Br J Ophthalmol       Date:  1996-08       Impact factor: 4.638

6.  A case-control study of post-traumatic endophthalmitis at a Spanish hospital.

Authors:  Maria Angeles Asencio; María Huertas; Rafael Carranza; Jose Maria Tenias; Javier Celis; Fernando Gonzalez-del Valle
Journal:  Int Ophthalmol       Date:  2015-07-29       Impact factor: 2.031

7.  Pediatric posttraumatic endophthalmitis.

Authors:  Haixiang Wu; Xinyi Ding; Meng Zhang; Gezhi Xu
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-04-12       Impact factor: 3.117

8.  Vitreous penetration of orally administered gatifloxacin in humans.

Authors:  Seenu M Hariprasad; William F Mieler; Eric R Holz
Journal:  Trans Am Ophthalmol Soc       Date:  2002

9.  [Posttraumatic endophthalmitis : Complication following severe eye injury].

Authors:  C S Mayer; D A Loos
Journal:  Ophthalmologe       Date:  2016-06       Impact factor: 1.059

10.  Antimicrobial effectiveness of silicone oil, heavy silicone oil and perfluorodecaline against Bacillus cereus.

Authors:  Nurgül Örnek; Teoman Apan; Kemal Örnek; Fatih Günay
Journal:  Int Ophthalmol       Date:  2013-12-29       Impact factor: 2.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.